ClinicalTrials.gg

Program

Nivolumab

Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.

Furthest: phase 4, since Nov 2, 2015145 company-led studies, 14 open or runningNext primary completion: Feb 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb12410 open or runningphase 4since Nov 2, 2015Feb 27, 2007Feb 5, 2027phase 2 · NCT06946797
Ono Pharmaceutical144 open or runningphase 3since Oct 9, 2014Jan 26, 2009Dec 31, 2027phase 2 · NCT04566380
Pfizer20 open or runningphase 2since Oct 7, 2015Oct 7, 2015none ahead
ella-therapeutics-ltd10 open or runningphase 2since Aug 13, 2020Aug 13, 2020none ahead
excellabio-llc10 open or runningphase 2since Oct 20, 2017Oct 20, 2017none ahead
nilogen-oncosystems10 open or runningearly phase 1since Dec 3, 2017Dec 3, 2017none ahead
rampart-health-l-l-c10 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead
USWM CT10 open or runningphase 2since Oct 26, 2022Oct 26, 2022none ahead

Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Halozyme Therapeutics, medarex, parexel, Astellas Pharma, akamis-bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and ppd-development-lp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 47 studies since Mar 28, 2017.

  1. Oct 6, 2021Phase 3 study in Stomach NeoplasmsOno Pharmaceutical · NCT05144854 · 626 enrolled · Japan, South Korea, Taiwan
  2. Nov 18, 2021Phase 2 study in Mesothelioma, MalignantBristol-Myers Squibb · NCT05136677 · 102 enrolled · China
  3. Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinBristol-Myers Squibb · NCT05255601 · 5 enrolled · United States, Australia, France and more
  4. Aug 9, 2022Phase 2 study in MelanomaBristol-Myers Squibb · NCT05496192 · Germany, Spain
  5. Aug 10, 2022Phase 1 study in Advanced Solid TumorsBristol-Myers Squibb · NCT05498480 · 6 enrolled · China
  6. Oct 26, 2022USWM CT's first study: phase 2 study in Ovarian NeoplasmsNew to USWM CTUSWM CT · NCT05601752 · 21 enrolled · United States, Canada, France and more
  7. Nov 15, 2022Phase 3 study in MelanomaBristol-Myers Squibb · NCT05625399 · 579 enrolled · United States, Australia, Austria and more
  8. Oct 20, 2023Phase 2 study in MelanomaBristol-Myers Squibb · NCT06101134 · 100 enrolled · United States, Chile, Greece and more
  9. Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06561386 · 1,000 planned · United States, Argentina, Australia and more
  10. Sep 30, 2024Phase 2 study in Rhabdoid TumorOno Pharmaceutical · NCT06622941 · 23 planned · Japan
  11. Apr 13, 2025Phase 2 study in Richter's TransformationOno Pharmaceutical · NCT06936943 · 14 planned · Japan
  12. Apr 25, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06946797 · 76 enrolled · United States, Brazil, Chile and more
  13. Mar 5, 2026Phase 4 study in MelanomaBristol-Myers Squibb · NCT07459543 · 40 planned · India
  14. Oct 14, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT04566380

Ahead

  1. Feb 5, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06946797
  2. Dec 31, 2027Primary completion: phase 2 study in Pan-tumorOno Pharmaceutical · NCT04566380
  3. Jan 31, 2029Primary completion: phase 2 study in Rhabdoid TumorOno Pharmaceutical · NCT06622941
  4. May 26, 2029Primary completion: phase 4 study in MelanomaBristol-Myers Squibb · NCT07459543

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The newest 60 of 145 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07459543Melanoma · India4Not yet recruitingBristol-Myers SquibbMay 26, 202940
NCT06946797Carcinoma, Non-Small-Cell Lung · United States, Brazil, Chile and more2Active, not recruitingBristol-Myers SquibbFeb 5, 202776
NCT06936943Richter's Transformation · Japan2RecruitingOno PharmaceuticalJul 31, 202914
NCT06622941Rhabdoid Tumor · Japan2RecruitingOno PharmaceuticalJan 31, 202923
NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbJul 30, 20301,000
NCT06101134Melanoma · United States, Chile, Greece and more2Active, not recruitingBristol-Myers SquibbApr 10, 2025100
NCT05625399Melanoma · United States, Australia, Austria and more3Active, not recruitingBristol-Myers SquibbAug 4, 2025579
NCT05601752Ovarian Neoplasms · United States, Canada, France and more2TerminatedUSWM CTSep 30, 202521
NCT05498480Advanced Solid Tumors · China1CompletedBristol-Myers SquibbJan 18, 20246
NCT05496192Melanoma · Germany, Spain2WithdrawnBristol-Myers SquibbJun 24, 20240
NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more2TerminatedBristol-Myers SquibbDec 3, 20255
NCT05136677Mesothelioma, Malignant · China2CompletedBristol-Myers SquibbNov 12, 2025102
NCT05144854Stomach Neoplasms · Japan, South Korea, Taiwan3Active, not recruitingOno PharmaceuticalOct 20, 2025626
NCT04567615Carcinoma, Hepatocellular · Argentina, Brazil, Chile and more2CompletedBristol-Myers SquibbAug 31, 2023266
NCT04566380Pan-tumor · Japan, South Korea, Taiwan2RecruitingOno PharmaceuticalDec 31, 202770
NCT04521075Melanoma · Israel2UNKNOWNella-therapeutics-ltdJul 1, 202242
NCT04513522Kidney Neoplasms · India4CompletedBristol-Myers SquibbJan 4, 2024101
NCT04495010Melanoma · United States, Australia, Austria and more2WithdrawnBristol-Myers SquibbFeb 28, 20240
NCT04340193Liver Neoplasms · United States, Australia, Austria and more3CompletedBristol-Myers SquibbDec 12, 202326
NCT04311710Neoplasms · United States, Italy, New Zealand1TerminatedBristol-Myers SquibbJan 14, 202121
NCT04209114Urinary Bladder Neoplasms · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbJun 7, 2023114
NCT04151563Carcinoma · United States, Argentina, Belgium and more2WithdrawnBristol-Myers SquibbDec 17, 20230
NCT04149574Urinary Bladder Neoplasms · United States, Argentina, Australia and more3TerminatedBristol-Myers SquibbOct 31, 202313
NCT04109066Breast Neoplasms · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbJan 16, 2023521
NCT04100018Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbJun 1, 20231,030
NCT04099251Melanoma · United States, Australia, Austria and more3Active, not recruitingBristol-Myers SquibbJun 28, 2022790
NCT04088500Carcinoma, Renal Cell · United States, Canada2TerminatedBristol-Myers SquibbNov 15, 20215
NCT04075604Breast Neoplasms · United States, Australia, Belgium and more2CompletedBristol-Myers SquibbJul 27, 202123
NCT04090775Metastatic Prostatic Adenocarcinoma · United States2Completedrampart-health-l-l-cJul 30, 202012
NCT04039607Carcinoma, Hepatocellular · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbJul 9, 2026732
NCT04026412Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbMar 22, 2024925
NCT04025879Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbJul 26, 2023461
NCT04008030Colorectal Neoplasms · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbAug 28, 2024839
NCT03980314Melanoma · United States, Argentina, Australia and more1CompletedBristol-Myers SquibbMar 4, 2021261
NCT03899155Neoplasms · United States, Argentina, Australia and more2RecruitingBristol-Myers SquibbAug 25, 20291,500
NCT03770299Carcinoma, Non-Small-Cell Lung2WithdrawnBristol-Myers SquibbMar 14, 20230
NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more2WithdrawnBristol-Myers SquibbFeb 27, 20220
NCT03668119Pan Tumor · United States, Argentina, Australia and more2CompletedBristol-Myers SquibbMay 3, 2022212
NCT03661320Urinary Bladder Neoplasms · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbFeb 16, 2026855
NCT03656718Neoplasms by Site · United States, Argentina, Brazil and more2CompletedBristol-Myers SquibbSep 7, 2022139
NCT03646123Hodgkin Disease · United States, Australia, Czechia and more2TerminatedPfizerNov 7, 2022255
NCT03519256Urinary Bladder Neoplasms · United States, Argentina, Australia and more2TerminatedBristol-Myers SquibbAug 22, 2022142
NCT03444766Carcinoma, Non-Small-Cell Lung · India4CompletedBristol-Myers SquibbJul 17, 2019100
NCT03414983Colorectal Neoplasms · United States, Canada, Japan and more3CompletedBristol-Myers SquibbFeb 1, 2021196
NCT03383458Carcinoma, Hepatocellular · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbMay 27, 2026545
NCT03377361Colorectal Neoplasms · United States, Argentina, Australia and more2CompletedBristol-Myers SquibbNov 4, 2024325
NCT03371992Carcinoma, Non-Small-Cell Lung · United StatesEarly 1UNKNOWNnilogen-oncosystemsDec 202025
NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more3CompletedBristol-Myers SquibbOct 14, 201974
NCT03338790Prostatic Neoplasms · United States, Argentina, Australia and more2CompletedBristol-Myers SquibbJan 13, 2021292
NCT03342417Ovarian Neoplasms · United States2Terminatedexcellabio-llcMay 29, 20195
NCT03215706Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbAug 16, 2019719
NCT03195491Lung Neoplasms · China, Thailand3CompletedBristol-Myers SquibbJun 8, 2021400
NCT03195478Solid Tumor · China2CompletedBristol-Myers SquibbJan 5, 202437
NCT03143153Various Advanced Cancer · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbJan 18, 2021970
NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbFeb 12, 2020701
NCT03138512Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbSep 28, 20231,641
NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico3TerminatedBristol-Myers SquibbFeb 22, 202123
NCT03117049Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Taiwan3CompletedOno PharmaceuticalFeb 10, 2020550
NCT03130959Various Advanced Cancer · United States, Australia, Brazil and more2CompletedBristol-Myers SquibbMar 10, 2020166
NCT03098550Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2CompletedBristol-Myers SquibbJul 6, 2020105

How it is read

Names in the registry

  • “Nivolumab”, 115 entries
  • “nivolumab”, 18 entries
  • “ONO-4538”, 13 entries
  • “BMS-936558 (MDX-1106)”, 5 entries
  • “Nivolumab + Relatlimab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.